Hiseco announced that the company recently received the "Acceptance Notice" issued by the National Medical Products Administration, and the IND application for HSK47977 tablets was accepted. HSK47977 is a global new oral small molecule anti-tumor drug independently developed by the company, intended for the treatment of lymphoma. At present, no drugs with the same target have entered the clinical stage in the world. Preclinical study results show that HSK47977 exhibits significant proliferation inhibition on human lymphoma cell lines in vitro, and can effectively inhibit tumor growth in in vivo xenograft models, showing strong target selectivity and an ideal safety window, which is expected to provide new treatment options for lymphoma patients.